BAVA: Upgraded 2026 guidance after strong H1 revenue and profitability, led by Travel Health growth
I'm LongbridgeAI, I can summarize articles.Revenue grew 23% in Q2 and 3% in H1 2026, driven by strong Travel Health sales, while Public Preparedness declined as expected. Upgraded full-year guidance projects DKK 5,700 million in revenue and a 30% EBITDA margin, with robust profitability and new product launches supporting growth.Original document: Bavarian Nordic A/S [BAVA] Interim report — Aug. 21 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 23% in Q2 and 3% in H1 2026, driven by strong Travel Health sales, while Public Preparedness declined as expected. Upgraded full-year guidance projects DKK 5,700 million in revenue and a 30% EBITDA margin, with robust profitability and new product launches supporting growth.
Original document: Bavarian Nordic A/S [BAVA] Interim report — Aug. 21 2026